Population-Based Estimates of Survival Benefit Associated with Combined Modality Therapy in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer

被引:59
作者
Davidoff, Amy J. [1 ,2 ]
Gardner, James F.
Seal, Brian [3 ]
Edelman, Martin J. [2 ]
机构
[1] Univ Maryland, Dept Pharmaceut Hlth Serv Res, Sch Pharm, Baltimore, MD 21201 USA
[2] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[3] Sanofi Aventis Pharmaceut, Bridgewater, NJ USA
关键词
SEER; Lung cancer; Geriatric; Performance status; LEUKEMIA GROUP-B; COOPERATIVE-ONCOLOGY-GROUP; III COLON-CANCER; PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; THORACIC RADIOTHERAPY; RANDOMIZED TRIAL; CHEMORADIOTHERAPY; CISPLATIN;
D O I
10.1097/JTO.0b013e31820eed00
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Combined modality therapy (CMT; radiation and chemotherapy) is indicated for fit, elderly patients with inoperable, locally advanced non-small cell lung cancer. We used population level data to examine effects of CMT on survival. Methods: Medicare patients who are 66 years or older with locally advanced non-small cell lung cancer (stages IIIA and IIIB without pleural effusion) from 1997 to 2002 were identified in Surveillance Epidemiology and End Results-Medicare. Detailed insurance claims were used to characterize treatment modality (none, chemotherapy only, radiotherapy only [XRT-ONLY], or CMT). CMT was further categorized as sequential (CMT-SEQ), or concurrent chemoradiation alone (CMT-ONLY), with induction (CMT-IND), or with consolidation chemotherapy (CMT-CON). Nonparametric models estimated survival effects of treatment regimens, controlling for patient characteristics, including claims-based indicators of performance status. Propensity score analysis adjusted for treatment selection. Results: Of the 6325 patients, 66% received therapy, with 41% (N = 1745) receiving XRT-ONLY and 45% (N = 1909) receiving CMT (12.5% CMT-SEQ, 35.3% CMT-ONLY, 11.3% CMT-IND, and 20.3% with CMT-CON). CMT had a survival benefit relative to XRT-ONLY (hazard ratio: 0.782, 95% confidence interval: 0.750-0.816; additional 4.4 months median survival; adjusted 10.7% increase in 1-year survival). Relative to CMT-SEQ, concurrent CMT-ONLY was associated with an increased mortality risk, whereas CMT-IND regimens provided a survival benefit (hazard ratio: 0.731, 95% confidence interval: 0.600-0.891; additional 3.8 months; and adjusted 14.4% increase in 1-year survival). Conclusion: Survival benefits associated with CMT in clinical trials can extend to the elderly in routine care settings. CMT-ONLY is associated with the greatest mortality risk, suggesting that more gradual strategies (CMT-IND) may be more appropriate for the elderly population.
引用
收藏
页码:934 / 941
页数:8
相关论文
共 34 条
[1]  
[Anonymous], 1999, Applied Survival Analysis: Time-to-Event
[2]  
[Anonymous], 2003, Proc Am Soc Clin Oncol
[3]  
[Anonymous], P AM SOC CLIN ONCOL
[4]   Phase III study of the eastern cooperative oncology group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer [J].
Belani, CP ;
Wang, W ;
Johnson, DH ;
Wagner, H ;
Schiller, J ;
Veeder, M ;
Mehta, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3760-3767
[5]   Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol [J].
Belani, CP ;
Choy, H ;
Bonomi, P ;
Scott, C ;
Travis, P ;
Haluschak, J ;
Curran, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5883-5891
[6]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[7]  
DAVIDOFF AJ, 2010, J CLIN ONCOL S, V28, pS15
[8]   Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer [J].
Davidoff, Amy J. ;
Tang, Mei ;
Seal, Brian ;
Edelman, Martin J. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2191-2197
[9]   Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients The Role of the Medical Oncologist Evaluation [J].
Davidoff, Amy J. ;
Rapp, Thomas ;
Onukwugha, Ebere ;
Zuckerman, Ilene H. ;
Hanna, Nader ;
Pandya, Naimish ;
Mullins, C. Daniel .
MEDICAL CARE, 2009, 47 (12) :1229-1236
[10]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619